logo-loader
viewArecor

Arecor progresses with insulin candidate clinical trial

The product is designed to improve treatment for people living with Type I diabetes

Arecor - Arecor progresses with insulin candidate clinical trial
The private pharmaceutical firm expects preliminary results by the end of the year

Arecor Limited has completed the dosing and all patient visits in phase I of its ultra-rapid acting insulin candidate, AT247.

The private pharmaceutical firm, which conducted the trial in Austria, said it expects preliminary results by the end of the year.

WATCH: Arecor doses first patient in Phase I trial for ultra-rapid acting insulin product

The product is designed to improve treatment for people living with Type I diabetes, by accelerating insulin absorption to manage more effectively blood glucose levels, especially after meals.

“The completion of the AT247 Phase I clinical trial is an important step in our strategy to develop even faster-acting insulins targeted at improving treatment and healthcare outcomes for people living with Type I diabetes,” said chief executive Sarah Howell.

“I look forward to reporting the headline data from this Phase I study in due course, the first product in our proprietary development pipeline.”

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read